Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Processa Pharmaceuticals, Inc. - Common Stock (NQ: PCSA )

0.8500 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 798
Open 0.8500
Bid (Size) 0.8400 (16)
Ask (Size) 0.9856 (30)
Prev. Close 0.8500
Today's Range 0.8500 - 0.8500
52wk Range 0.8442 - 9.280
Shares Outstanding 3,266,944
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why Stitch Fix Shares Are Trading Higher By Around 21%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Why C3.ai Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
Via Benzinga

Performance

YTD
-87.98%
-87.98%
1 Month
-1.17%
-1.17%
3 Month
-37.49%
-37.49%
6 Month
-56.85%
-56.85%
1 Year
-89.85%
-89.85%

More News

Read More
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
PCSA Stock Earnings: Processa Pharma Reported Results for Q1 2024
Via InvestorPlace
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Reports Phase 2 Clinical Trial Dosing Has Commenced
Via Investor Brand Network
Constellation Brands, Levi Strauss And 3 Stocks To Watch Heading Into Thursday
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Participate at the H.C. Wainwright 26th Annual Global Investment Conference, ESMO Congress 2024
Via Investor Brand Network
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Q2 2024 Financial Results, Provides Updates
Via Investor Brand Network
Exposures Product Safety
BioMedNewsBreaks — Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Positive Data from Two Preclinical Studies of NGC-Iri
Via Investor Brand Network
PCSA Stock Earnings: Processa Pharma Misses EPS for Q2 2024
Via InvestorPlace
Nasdaq Down 1%; JetBlue Airways Shares Spike Higher
Via Benzinga
Crude Oil Down 1%; Procter & Gamble Shares Fall After Q4 Results
Via Benzinga
Exposures Fossil Fuels
Why Merck Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
2U (TWOU) Stock Continues to Surge in Bankruptcy Rally
Via InvestorPlace
Topics Bankruptcy
Exposures Financial Legal
Why Is Processa Pharmaceuticals (PCSA) Stock Up 29% Today?
Via InvestorPlace
InvestorNewsBreaks – Processa Pharmaceuticals Inc.’s (NASDAQ: PCSA) IND Application for Phase 2 Clinical Trial of NGC-Cap in Patients with Breast Cancer Receives FDA Clearance
Via Investor Brand Network
Exposures Product Safety
Dow Jumps 200 Points; Pfizer Earnings Top Views
Via Benzinga
Topics Stocks
Exposures US Equities
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Appoints Seasoned Veteran as Chief Financial Officer
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Positive Efficacy Results from Phase 1b Trial
Via Investor Brand Network
Exposures Product Safety
BioMedNewsBreaks — Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Participation at Upcoming EF Hutton Global Conference
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Appoints Dr. Steven Cha to Lead Clinical Development of Oncology Programs
Via Investor Brand Network
Exposures Product Safety
Why Aon Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Why Alphabet Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.